Enhancing the therapeutic potential of intravenous glycerol for Meniere's disease : Robust results from an extensive patient cohort
Copyright © 2023 Elsevier Inc. All rights reserved..
INTRODUCTION: Meniere's disease (MD) is an idiopatic condition characterized by recurrent attacks of vertigo, hearing loss, tinnitus, and aural fullness, affecting quality of life. Intravenous glycerol has shown potential as a therapeutic option. This study evaluates its efficacy in a larger patient cohort.
MATERIALS AND METHODS: Retrospective study with 168 patients having unilateral MD unresponsive to dietary restrictions. Intravenous 10 % glycerol with 0.9 % sodium chloride was administered for six months. Audio-vestibular assessments and questionnaires were used.
RESULTS: Significant improvements in vertigo control observed. 7.1 % achieved complete control, and 58.3 % had substantial control. Quality of life measures improved, and audiometry thresholds remained unchanged. No major adverse events reported.
DISCUSSION: Intravenous glycerol effectively controlled vertigo and improved MD patients' quality of life. Limitations include lack of a control group and a relatively short-term follow-up. Future prospects include randomized controlled trials and optimization of treatment protocols.
CONCLUSION: Intravenous glycerol shows promise as a therapeutic option for MD, with notable improvements in vertigo control and quality of life. Further research is needed for validation and optimization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
American journal of otolaryngology - 45(2023), 1 vom: 18. Jan., Seite 104093 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Scarpa, Alfonso [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gentamicin |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjoto.2023.104093 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364164158 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364164158 | ||
| 003 | DE-627 | ||
| 005 | 20231227133143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjoto.2023.104093 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1230.xml |
| 035 | |a (DE-627)NLM364164158 | ||
| 035 | |a (NLM)37924560 | ||
| 035 | |a (PII)S0196-0709(23)00307-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scarpa, Alfonso |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancing the therapeutic potential of intravenous glycerol for Meniere's disease |b Robust results from an extensive patient cohort |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: Meniere's disease (MD) is an idiopatic condition characterized by recurrent attacks of vertigo, hearing loss, tinnitus, and aural fullness, affecting quality of life. Intravenous glycerol has shown potential as a therapeutic option. This study evaluates its efficacy in a larger patient cohort | ||
| 520 | |a MATERIALS AND METHODS: Retrospective study with 168 patients having unilateral MD unresponsive to dietary restrictions. Intravenous 10 % glycerol with 0.9 % sodium chloride was administered for six months. Audio-vestibular assessments and questionnaires were used | ||
| 520 | |a RESULTS: Significant improvements in vertigo control observed. 7.1 % achieved complete control, and 58.3 % had substantial control. Quality of life measures improved, and audiometry thresholds remained unchanged. No major adverse events reported | ||
| 520 | |a DISCUSSION: Intravenous glycerol effectively controlled vertigo and improved MD patients' quality of life. Limitations include lack of a control group and a relatively short-term follow-up. Future prospects include randomized controlled trials and optimization of treatment protocols | ||
| 520 | |a CONCLUSION: Intravenous glycerol shows promise as a therapeutic option for MD, with notable improvements in vertigo control and quality of life. Further research is needed for validation and optimization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Gentamicin | |
| 650 | 4 | |a Hearing loss | |
| 650 | 4 | |a Intratympanic injection | |
| 650 | 4 | |a Meniere disease | |
| 650 | 4 | |a Vertigo | |
| 650 | 7 | |a Glycerol |2 NLM | |
| 650 | 7 | |a PDC6A3C0OX |2 NLM | |
| 650 | 7 | |a Gentamicins |2 NLM | |
| 700 | 1 | |a Carucci, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Salzano, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Avallone, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Cassandro, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarella, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Ricciardiello, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Ralli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Viola, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Salzano, Francesco Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of otolaryngology |d 1993 |g 45(2023), 1 vom: 18. Jan., Seite 104093 |w (DE-627)NLM000961876 |x 1532-818X |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2023 |g number:1 |g day:18 |g month:01 |g pages:104093 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjoto.2023.104093 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2023 |e 1 |b 18 |c 01 |h 104093 | ||